Moreover, SREBP-1c is a major transcription factor regulating lipogenesis and its downstream targets FAS, ACC, and SCD, and its activation aggravates the symptoms of NAFLD [47]. This evidence concerns the gene SCD and metabolic dysfunction-associated steatotic liver disease.